Predictive ability of direct-to-consumer pharmacogenetic testing: When is lack of evidence really lack of evidence?

2013-03-11

Pharmacogenomics , Volume 14 - Issue 4 p. 341- 344

Additional Metadata
Keywords	CYP2C19 gene, HLA DR gene, clinical practice, consumer advocacy, consumer attitude, drug efficacy, drug response, evidence based medicine, food and drug administration, gene, gene frequency, gene function, gene identification, genetic association, genetic screening, genotyping technique, human, marketing, medical research, pharmacogenetics, prediction, review, sensitivity and specificity, slco1b1 gene
Persistent URL	doi.org/10.2217/pgs.13.8, hdl.handle.net/1765/40825
Journal	Pharmacogenomics
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Kalf, R., Bakker, R.& Janssens, C. (2013). Predictive ability of direct-to-consumer pharmacogenetic testing: When is lack of evidence really lack of evidence?. In Pharmacogenomics (Vol. 14, Number 4, pp. 341–344).https://doi.org/10.2217/pgs.13.8

Publication